bloodjournal

Menu

  • Home
  • About
    • Aims and Scope
    • Editorial board
    • Indexing and Abstracting
    • Peer Review
    • Publishing Ethics and Malpractice Statement
    • Open Access Policy and Publication Fee
  • Archive
    • 2023
      • № 1/2023
    • 2022
      • № 1/2022
      • № 2/2022
      • № 3/2022
      • № 4/2022
    • 2021
      • № 1/2021
      • № 2/2021
      • № 3/2021
      • № 4/2021
    • 2020
      • № 1/2020
      • № 2/2020
      • № 3/2020
      • № 4/2020
    • 2019
      • №1/2019
      • № 2/2019
      • № 3/2019
      • № 4/2019
    • 2018
      • №1/2018
      • №2/2018
      • №3/2018
      • №4/2018
    • 2017
      • №1/2017
      • №2/2017
      • №3/2017
      • №4/2017
    • 2016
      • №1/2016
      • №2/2016
      • №3/2016
      • №4/2016
    • 2015
      • №1/2015
      • №2/2015
      • №3/2015
      • №4/2015
    • 2014
      • № 1/2014
      • №2/2014
      • №3/2014
      • №4/2014
    • 2013
      • №1/2013
      • №2/2013
      • №3/2013
      • №4/2013
  • Submission
    • Submit manuscript

Perspectives for the Use of Bispecific Antibodies in the Third- and Subsequent-Line Therapies of Follicular Lymphoma (Resolution of Expert Panel)

AUTOIMMUNE THROMBOCYTOPENIA

Read in PDF

  • ← The Prognostic Role of Genetic Aberrations in Mantle Cell Lymphoma: A Literature Review and Clinical Experience

Login

Registration

Languages

  • ru 
  • en 

Advanced search

get_results("SELECT name, label FROM `wp_mf_custom_fields`");
echo '

';
echo '

';
foreach($query as $q)
{
$val = "";
if(isset($_REQUEST[$q->name]))
{
$val = $_REQUEST[$q->name];
}
if($q->name != 'files'){
echo '';
}
}
echo '';
echo '

';
echo '

';
?>


New Articles

  • Perspectives for the Use of Bispecific Antibodies in the Third- and Subsequent-Line Therapies of Follicular Lymphoma (Resolution of Expert Panel)
  • The Prognostic Role of Genetic Aberrations in Mantle Cell Lymphoma: A Literature Review and Clinical Experience
  • Ibrutinib Efficacy in First-Line Therapy of High-Risk Patients Vs. Second- and Third-Line Therapies of Resistant Chronic Lymphocytic Leukemia
  • Plasma Cell-Free DNA in Patients with Diffuse Large B-Cell and B-Cell High-Grade (Double Hit/Triple Hit) Lymphomas
  • Long-Term Results of Classical Hodgkin’s Lymphoma Treatment in Real-World Clinical Practice: Experience of Novosibirsk Hematological Unit

Our contacts

«PRACTICAL MEDICINE» LLC PUBLISHING HOUSE

115201, Moscow, 1st Kotlyakovsky Pereulok 3

Phone. +7 (495) 324-93-29

E-mail: bj@medprint.ru

www.medprint.ru